Preparing for Tuberculosis Vaccine M72/AS01E Implementation
This correction relates to the global demand forecast for the potential implementation of the M72/AS01E TB vaccine
Zambia
TB vaccine development: monitoring international patent filings to anticipate access challenges
Maps international patent filings for two late-stage TB vaccine candidates, MTBVAC and M72/AS01E, as well as the QS-21 adjuvant used in M72/AS01E
ZAMSA-TB: Advancing epidemiological methods for surveillance of Mycobacterium tuberculosis infection
Multi-country study developing and validating clinic-based convenience sampling of Mtb immunoreactivity (IGRA) in children aged 1-5 as a sentinel measure of recent TB transmission. Outputs include geospatial identification of high-transmission neighbourhoods to target adult/adolescent vaccine delivery, and Monte Carlo simulations to size convenience-sampling surveys able to detect population-level vaccine effectiveness during roll-out.
The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries
Estimates the potential economic impact of introducing novel TB vaccines in 105 low- and middle- income countries. It compares ifnant and adolescents/ adult vaccination scenarios and models their effects on TB- related mortality, morbidity, healthcare costs and GDP. Finding support decision making on the future development and introduciton of novel TB vaccines
Facing up to reality? What to do if M72/AS01E doses are limited
The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a
positive result, could be licensed by 2030. Modelling suggested a large potential impact from
introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is
likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding
the allocation of constrained doses on the potential global impact of M72/AS01E
Willingness to receive a future adult tuberculosis vaccine in Lusaka, Zambia: Perspectives from community members and healthcare workers
One or more new adult TB vaccines could become available in the next 5-7 years. To
assess willingness to receive a new TB vaccine, we conducted a household- and facility-based survey
among adult community members and healthcare workers (HCWs), respectively, in Lusaka, Zambia
Cost and Cost Effectiveness of Novel Tuberculosis Vaccines in Low-and Middle-income Countries: A Systematic Review of Modelling Studies
This review addressed the costs and cost-effectiveness of novel tuberculosis (TB) vaccines compared to the current standard of care (BCG) in various settings and for different age groups in LMICs
Prevention is better than cure’: a mixed methods study of communities’ and healthcare workers’ perspectives on new adult and adolescent TB vaccines and their implementation in Zambia
Mixed methods study examining community members' and healthcare workers' views on future TB vaccines for adults and adolescents in Zamibia. It assesses willingness to receive a TB vaccine, preferred vaccine characteristics, concerns about safety and efficacy, trusted information sources, barriers to uptake, and preferred approaches for vaccine delivery and implementation.
The potential health and economic impact of introducing the vaccine candidate VPM1002 to prevent tuberculosis disease in low- and middle-income countries
This study estimates the potential health and economic impact of introducing the TB vaccine candidate VPM1002 in 79 low- and middle- income countries. It models routine vaccination and vaccination campaigns, estimating TB cases and deaths averted and the cost-effectiveness of different introduction scenarios. It provides evidence for decisions about the potential future introduction and scale-up of VPM1002
Modelling to estimate the health impact of novel tuberculosis vaccines on TB burden in people living with HIV
This project will inform tuberculosis (TB) prevention efforts by estimating the health impact of novel tuberculosis vaccines on TB burden in people living with HIV (PLHIV) using a novel Mycobacterium tuberculosis transmission model. HIV confers the largest relative risk of TB, and new TB vaccines could be an important tool to prevent TB; however, modelling studies have not systematically investigated how new vaccines will affect TB burden in PLHIV. In stage 1 of this project, we aim to investigate TB vaccine impact in PLHIV where vaccine product characteristics and delivery vary by recipient HIV status. In stage 2, we aim to quantify how complex vaccine targeting strategies and incorporating additional granularity in HIV/AIDS natural history might affect vaccine impact estimates in PLHIV